)
)
)
Rallidae Therapeutics
Rallidae Therapeutics is developing vasopressin V1aR partial agonists as next gen pressors for vasodilatory hypotension, a key driver of acute kidney injury in cirrhotic liver disease, vasodilatory shock, and CKD. Safety and efficacy of the Rallidae approach is clinically validated, with a clear path to a once weekly SC NCE, transforming care for patients in large markets with few therapeutic solutions today.
We are talking with partners and investors to advance discovery and development of V1aR partial agonists, preventing renal injury and other consequences of vasodilatory hypotension.
Address
San DiegoCalifornia
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)